Login to Your Account

Synpromics raises $6.7M to help advance cell, gene therapy

By Nuala Moran
Staff Writer

Wednesday, April 19, 2017

LONDON – Synpromics Ltd has raised £5.2 million in a series B round to advance the development and commercialization of its synthetic promoter technology for controlling and directing gene expression.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription